论文部分内容阅读
急性心梗的溶栓疗法目的使梗塞冠脉再灌注。冠脉内溶栓须要紧急心导管术,因此价值有限,乃使静脉溶栓得以广泛应用。以往,作为再灌注的标识就是胸痛缓解、ST段不再抬高、出现特殊心律失常。另外,急性闭塞的冠脉再灌注之后,CK和CK-MB活性与其它心肌酶一样早期升高。然而,作为血管再通的指征,这些非侵入性标准既不敏感,也不特异。甚至当它们联合应用时,只在一致升高的时候,其预测正确性才会增高,遗憾的是只有14％再灌注的患者
Thrombolytic therapy for acute myocardial infarction aims to reperfuse the infarcted coronary artery. Intracoronary thrombolysis requires urgent cardiothoracic surgery, so the value is limited, so that intravenous thrombolysis can be widely used. In the past, as a marker of reperfusion is to relieve chest pain, ST segment is no longer elevated, there are special arrhythmias. In addition, CK and CK-MB activity was elevated early after acute coronary occlusion and other myocardial enzymes. However, as an indication of recanalization, these non-invasive criteria are neither sensitive nor specific. Even when they are used in combination, their predictive accuracy increases only when they are uniformly elevated, regrettably, only 14% of patients reperfused